Institution
University of Nebraska Omaha
Education•Omaha, Nebraska, United States•
About: University of Nebraska Omaha is a education organization based out in Omaha, Nebraska, United States. It is known for research contribution in the topics: Population & Poison control. The organization has 4526 authors who have published 8905 publications receiving 213914 citations. The organization is also known as: UNO & University of Omaha.
Papers published on a yearly basis
Papers
More filters
••
TL;DR: In this article, the authors trace the history of behavioral genetics and show that the Burt and Simons critique dates back 40 years and has been subject to a broad array of empirical investigations, and that the violation of assumptions in twin models does not invalidate their results.
Abstract: In a recent article published in Criminology, Burt and Simons (2014) claimed that the statistical violations of the classical twin design render heritability studies useless. Claiming quantitative genetics is “fatally flawed” and describing the results generated from these models as “preposterous,” Burt and Simons took the unprecedented step to call for abandoning heritability studies and their constituent findings. We show that their call for an “end to heritability studies” was premature, misleading, and entirely without merit. Specifically, we trace the history of behavioral genetics and show that 1) the Burt and Simons critique dates back 40 years and has been subject to a broad array of empirical investigations, 2) the violation of assumptions in twin models does not invalidate their results, and 3) Burt and Simons created a distorted and highly misleading portrait of behavioral genetics and those who use quantitative genetic approaches. “The flaws of twin studies are not fatal, but rather seem no worse (and may be better) than the flaws of the typical causal study that relies on observational data.” (Felson, 2012: ii)
145 citations
••
Imperial College Healthcare1, American University of Beirut2, University of Miami3, Washington University in St. Louis4, Memorial Sloan Kettering Cancer Center5, St Thomas' Hospital6, University College London7, Imperial College London8, National Institutes of Health9, Federal University of Bahia10, Cornell University11, University of Nebraska Omaha12, Mashhad University of Medical Sciences13, Nagasaki University14, Iwate Medical University15, Kagoshima University16, University of the Ryukyus17, University of Tokyo18, Kyoto University19, Hamamatsu University School of Medicine20, Kumamoto University21, Saitama Medical University22
TL;DR: This expert consensus highlights the need for additional clinical trials to develop novel standard therapies for the treatment of ATL and recommends up-front allogeneic hematopoietic stem-cell transplantation and novel agents.
Abstract: PurposeAdult T-cell leukemia-lymphoma (ATL) is a distinct mature T-cell malignancy caused by chronic infection with human T-lymphotropic virus type 1 with diverse clinical features and prognosis. ATL remains a challenging disease as a result of its diverse clinical features, multidrug resistance of malignant cells, frequent large tumor burden, hypercalcemia, and/or frequent opportunistic infection. In 2009, we published a consensus report to define prognostic factors, clinical subclassifications, treatment strategies, and response criteria. The 2009 consensus report has become the standard reference for clinical trials in ATL and a guide for clinical management. Since the last consensus there has been progress in the understanding of the molecular pathophysiology of ATL and risk-adapted treatment approaches.MethodsReflecting these advances, ATL researchers and clinicians joined together at the 18th International Conference on Human Retrovirology—Human T-Lymphotropic Virus and Related Retroviruses—in Tokyo...
144 citations
••
TL;DR: This article applied new time series procedures to examine the Prebisch-singer hypothesis of a secular deterioration in relative primary commodity prices and found that the trend is not well represented by a single downward slope, but instead by a shifting trend that often changes sign over the sample period.
144 citations
••
TL;DR: The most primitive lavas (picritic and olivine-phyric basalts) recovered from the young-looking flows within the A-B strike-slip fault in the western portion of the Siqueiros transform domain were found to contain millimeter-sized olivines (up to 20 modal%) that have a limited compositional range.
144 citations
••
TL;DR: Minocycline is an effective DMARD in patients with early seropositive rheumatoid arthritis and did so while receiving less prednisone, compared with a conventional disease-modifying antirheumatic drug, hydroxychloroquine.
Abstract: Objective
To compare the efficacy of minocycline with that of a conventional disease-modifying antirheumatic drug (DMARD), hydroxychloroquine, in patients with early seropositive rheumatoid arthritis (RA).
Methods
Sixty patients with seropositive RA of <1 year's duration who had not been previously treated with DMARDs were randomized to receive minocycline, 100 mg twice per day, or hydroxychloroquine, 200 mg twice per day, in a 2-year, double-blind protocol. All patients also received low-dose prednisone. The primary end points of the study were 1) the percentage of patients with an American College of Rheumatology (ACR) 50% improvement (ACR50) response at 2 years, and 2) the dosage of prednisone at 2 years.
Results
Minocycline-treated patients were more likely to achieve an ACR50 response at 2 years compared with hydroxychloroquine-treated patients (60% compared with 33%, respectively; P = 0.04). Minocycline-treated patients were also receiving less prednisone at 2 years compared with the hydroxychloroquine group (mean 0.81 mg/day compared with 3.21 mg/day, respectively; P < 0.01). In addition, patients treated with minocycline were more likely to have been completely tapered off prednisone (P = 0.03). Trends favoring the minocycline treatment group were seen when outcomes were assessed according to components of the ACR core criteria set, with the differences reaching statistical significance for patient's global assessment of disease activity (P = 0.004).
Conclusion
Minocycline is an effective DMARD in patients with early seropositive RA. Patients treated with minocycline were more likely to achieve an ACR50 response and did so while receiving less prednisone. In addition, minocycline-treated patients were more likely to have discontinued treatment with prednisone at 2 years.
144 citations
Authors
Showing all 4588 results
Name | H-index | Papers | Citations |
---|---|---|---|
Darell D. Bigner | 130 | 819 | 90558 |
Dan L. Longo | 125 | 697 | 56085 |
William B. Dobyns | 105 | 430 | 38956 |
Eamonn Martin Quigley | 103 | 685 | 39585 |
Howard E. Gendelman | 101 | 567 | 39460 |
Alexander V. Kabanov | 99 | 447 | 34519 |
Douglas T. Fearon | 94 | 278 | 35140 |
Dapeng Yu | 94 | 745 | 33613 |
John E. Wagner | 94 | 488 | 35586 |
Zbigniew K. Wszolek | 93 | 576 | 39943 |
Surinder K. Batra | 87 | 564 | 30653 |
Frank L. Graham | 85 | 255 | 39619 |
Jing Zhou | 84 | 533 | 37101 |
Manish Sharma | 82 | 1407 | 33361 |
Peter F. Wright | 77 | 252 | 21498 |